Jeffery Nelson
Neurology · Lovington, NMNPI 1417922212
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 363 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 28.9% of the total.
Across 363 payments — averaging $14.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$798
- Lilly USA, LLC$304
- Biogen$287
- Novartis$262
- Amgen$204
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$140%
- Food & beverage$5,02199%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 133 | $1,469 |
| AbbVie(2 entities) | 80 | $798 |
| Lilly USA, LLC | 12 | $304 |
| Biogen | 14 | $287 |
| Novartis | 17 | $262 |
| Amgen | 16 | $204 |
| CSL Behring | 12 | $198 |
| UCB, Inc. | 7 | $176 |
| Jazz Pharmaceuticals Inc. | 9 | $154 |
| Axsome Therapeutics, Inc. | 6 | $146 |
| Upsher-smith Laboratories LLC | 9 | $141 |
| Stryker | 1 | $123 |
| EMD Serono, Inc. | 7 | $106 |
| Harmony Biosciences LLC | 4 | $81 |
| AstraZeneca | 5 | $73 |
| SK Life Science, Inc. | 3 | $55 |
| Pfizer | 2 | $51 |
| Exeltis, USA Inc. | 2 | $39 |
| Neurelis, Inc. | 2 | $39 |
| Millicent US Inc | 2 | $38 |
| Neurocrine Biosciences, Inc. | 2 | $35 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Lundbeck LLC | 2 | $33 |
| Eisai Inc. | 2 | $33 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $31 |
| Scilex Pharmaceuticals Inc. | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $29 |
| Saol Therapeutics Inc. | 1 | $28 |
| Tonix Medicines, Inc. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Grifols USA, LLC | 1 | $15 |
| Bristol Myers Squibb | 1 | $15 |
| Acorda Therapeutics, Inc | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$126
- NSE - SUMEX DRILL$123
- NSE - ROUTERS$123
- EMGALITY$120
How this compares
$5,089 in reported general payments places this provider in the 80th percentile of 91 neurology providers in New Mexico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sodium Oxybate | 23 | $311,604 |
| MayzentSiponimod | 12 | $248,225 |
| XcopriCenobamate | 19 | $52,241 |
| Aimovig AutoinjectorErenumab-Aooe | 45 | $50,032 |
| Emgality PenGalcanezumab-Gnlm | 53 | $48,722 |
| BriviactBrivaracetam | 30 | $45,437 |
| GlatopaGlatiramer Acetate | 14 | $37,632 |
| AptiomEslicarbazepine Acetate | 12 | $28,537 |
| Nurtec OdtRimegepant Sulfate | 11 | $20,075 |
| Carbamazepine ErCarbamazepine | 148 | $19,136 |
| Oxtellar XrOxcarbazepine | 12 | $16,052 |
| Levetiracetam | 313 | $14,139 |
| EliquisApixaban | 21 | $12,112 |
| FingolimodFingolimod Hcl | 19 | $11,182 |
| BelsomraSuvorexant | 14 | $9,315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisMayzent | $262 | $248,22512 claims |
| UCB, Inc.Briviact, Nayzilam | $176 | $52,57841 claims |
| SK Life Science, Inc.Xcopri | $55 | $52,24119 claims |
| PfizerNurtec Odt, Eliquis, Dilantin | $51 | $37,45151 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $34 | $16,05212 claims |
| AbbVieSavella | $798 | $8,89212 claims |
| Upsher-smith Laboratories LLCTopiramate | $141 | $3,039231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 91 neurology providers in New Mexico.
Other neurology in Lovington
- Elaine EdmondsAlbuquerque$610K
- Kader AbdelerahmanAlbuquerque$607K
- Weiwei DaiRio Rancho$367K
- Timothy OwnbeyAlbuquerque$90K
- Gerson Suarez CedenoAlbuquerque$44K
- Corey FordAlbuquerque$27K
- Diksha MohantyAlbuquerque$20K
- Douglas BarrettAlbuquerque$19K
- Vanessa Licona SanjuanAlbuquerque$16K
- Daniel ShibuyaAlbuquerque$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.